These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 28230637)

  • 1. mTOR Inhibition and Cardiovascular Diseases: Cardiac Hypertrophy.
    Paoletti E
    Transplantation; 2018 Feb; 102(2S Suppl 1):S41-S43. PubMed ID: 28230637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression of left ventricular hypertrophy in kidney transplant recipients: the potential role for inhibition of mammalian target of rapamycin.
    Paoletti E; Cannella G
    Transplant Proc; 2010 Nov; 42(9 Suppl):S41-3. PubMed ID: 21095451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTOR Inhibition and Clinical Transplantation: Kidney.
    Flechner SM
    Transplantation; 2018 Feb; 102(2S Suppl 1):S17-S18. PubMed ID: 28230636
    [No Abstract]   [Full Text] [Related]  

  • 4. mTOR Inhibition and Kidney Diseases.
    Ma MKM; Yung S; Chan TM
    Transplantation; 2018 Feb; 102(2S Suppl 1):S32-S40. PubMed ID: 29369972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR Inhibition and Clinical Transplantation: Pancreas and Islet.
    Berney T; Andres A; Toso C; Majno P; Squifflet JP
    Transplantation; 2018 Feb; 102(2S Suppl 1):S30-S31. PubMed ID: 28230643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial.
    Paoletti E; Amidone M; Cassottana P; Gherzi M; Marsano L; Cannella G
    Am J Kidney Dis; 2008 Aug; 52(2):324-30. PubMed ID: 18585837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammalian Target of Rapamycin Inhibitor Monotherapy: Efficacy in Renal Transplantation.
    Franco A; Más-Serrano P; Perez Contreras J; Jiménez L; Rodriguez D; Olivares J
    Transplant Proc; 2015 Oct; 47(8):2364-7. PubMed ID: 26518928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of mTOR inhibitors in the regression of left ventricular hypertrophy in elderly kidney transplant recipients.
    David-Neto E; Filho MPM; de Sá ÍJAS; Agena F; de Andrade JL; de Paula FJ
    Clin Transplant; 2022 Aug; 36(8):e14742. PubMed ID: 35678134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTOR Inhibition and Clinical Transplantation: Heart.
    Zuckermann A; Osorio-Jaramillo E; Aliabadi-Zuckermann AZ
    Transplantation; 2018 Feb; 102(2S Suppl 1):S27-S29. PubMed ID: 29369971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion therapy to everolimus in renal transplant recipients: results after one year.
    Giron F; Baez Y; Niño-Murcia A; Rodríguez J; Salcedo S
    Transplant Proc; 2008 Apr; 40(3):711-3. PubMed ID: 18454994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing the risk of left ventricular hypertrophy in kidney transplant recipients: the potential role of mammalian target of rapamycin.
    Paoletti E; Cannella G
    Transplant Proc; 2009; 41(6 Suppl):S3-5. PubMed ID: 19651293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Long Journey of mTOR Inhibitors and the Long Path That Is Still Ahead.
    Tedesco Silva H
    Transplantation; 2018 Feb; 102(2S Suppl 1):S1-S2. PubMed ID: 29369969
    [No Abstract]   [Full Text] [Related]  

  • 13. mTOR Inhibition and Clinical Transplantation: Liver.
    Nashan B
    Transplantation; 2018 Feb; 102(2S Suppl 1):S19-S26. PubMed ID: 28230639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Everolimus-based Immunosuppression to Decrease Cytomegalovirus Infection After Kidney Transplant.
    Malvezzi P; Jouve T; Rostaing L
    Exp Clin Transplant; 2016 Aug; 14(4):361-6. PubMed ID: 27041365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients: a 1 year, randomized, controlled trial.
    Paoletti E; Marsano L; Bellino D; Cassottana P; Cannella G
    Transplantation; 2012 Mar; 93(5):503-8. PubMed ID: 22318246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic Review on Role of Mammalian Target of Rapamycin Inhibitors as an Alternative to Calcineurin Inhibitors in Renal Transplant: Challenges and Window to Excel.
    Kumar J; Bridson JM; Sharma A; Halawa A
    Exp Clin Transplant; 2017 Jun; 15(3):241-252. PubMed ID: 27915965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Advances in Mammalian Target of Rapamycin Inhibitor Use in Heart and Lung Transplantation.
    Fine NM; Kushwaha SS
    Transplantation; 2016 Dec; 100(12):2558-2568. PubMed ID: 27495747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients.
    Badve SV; Pascoe EM; Burke M; Clayton PA; Campbell SB; Hawley CM; Lim WH; McDonald SP; Wong G; Johnson DW
    Clin J Am Soc Nephrol; 2016 Oct; 11(10):1845-1855. PubMed ID: 27445164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evidence on the use of anti-mTOR drugs in renal transplantation.
    Hernández D; Martínez D; Gutiérrez E; López V; Gutiérrez C; García P; Cobelo C; Cabello M; Burgos D; Sola E; González-Molina M
    Nefrologia; 2011; 31(1):27-34. PubMed ID: 21270910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
    Diekmann F; Andrés A; Oppenheimer F
    Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.